- Conditions
- Uveal Melanoma, Liver Metastases
- Interventions
- CVA21, Ipilimumab
- Biological
- Lead sponsor
- Viralytics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Miami Beach, Florida • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 203
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uveal Melanoma
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Miami Beach, Florida • New York, New York • Columbus, Ohio
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Uveal Melanoma
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
- Interventions
- Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
- Combination Product
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
- Interventions
- [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
- Drug · Biological
- Lead sponsor
- Fusion Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Uveal Melanoma
- Interventions
- BVD-523
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Choroidal Melanoma
- Interventions
- TTT + ICG-based PDT
- Procedure
- Lead sponsor
- New England Retina Associates
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hamden, Connecticut
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- TBio-4101, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Turnstone Biologics, Corp.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Interventions
- vorinostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Rockledge, Pennsylvania
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Interventions
- RO7293583, Tocilizumab, Obinutuzumab, Adalimumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
- Interventions
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveal Melanoma
- Interventions
- stereotactic body radiotherapy, Immunotherapy
- Radiation · Drug
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Uveal Melanoma
- Interventions
- ADI PEG20, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- pyrazoloacridine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Melanoma
- Interventions
- Lifileucel (LN-144)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Choroidal Melanoma, Indeterminate Lesions
- Interventions
- Observational
- Other
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 10
- States / cities
- Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
- Conditions
- Stage IV Uveal Melanoma
- Interventions
- Sir-Spheres®
- Device
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
- Interventions
- Not listed
- Lead sponsor
- Mohamed Abdel-Rahman
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Interventions
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Uveal Melanoma in the Liver
- Interventions
- SD-101, Nivolumab, Ipilimumab, Nivolumab and Relatlimab
- Drug · Biological
- Lead sponsor
- TriSalus Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
- Conditions
- Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
- Interventions
- Pembrolizumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Nashville, Tennessee